SCHEMBL310471

SCHEMBL310471

CCOc1cc(-c2ccncc2)ccc1[N+](=O)[O-]

nearest known ligand 0.65

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 2/20 0.65
CYP11B2 P19099 2/20 0.65
MAPT P10636 5/20 0.51
S1PR1 P21453 7/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
CHEK1 O14757 2/20 0.45
ALDH1A1 P00352 4/20 0.45
LMNA P02545 2/20 0.45
S1PR3 Q99500 2/20 0.44
HPGD P15428 1/20 0.44
HSD17B10 Q99714 1/20 0.44
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
MAPK1 P28482 1/20 0.42
RECQL P46063 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL310270 0.84 CYP11B1 (0.59) CYP11B1CYP11B2MAPTKMT2ACHEK1
SCHEMBL15283758 0.80 CYP11B1 (0.55) CYP11B1CYP11B2CHEK1ALDH1A1NPC1
SCHEMBL10257321 0.80 MAPT (0.48) CYP11B1CYP11B2MAPTMEN1KMT2A
SCHEMBL5425254 0.78 MAPT (0.52) CYP11B1CYP11B2MAPTMEN1KMT2A
SCHEMBL5071215 0.77 MAPT (0.44) CYP11B1CYP11B2MAPTMEN1KMT2A
Potassium Ion SCHEMBL10540930 0.77 MAPT (0.57) CYP11B1CYP11B2MAPTMEN1KMT2A
SCHEMBL28087330 0.77 ALDH1A1 (0.50) CYP11B1CYP11B2MAPTMEN1KMT2A
SCHEMBL30679039 0.77 CYP11B1 (0.55) CYP11B1CYP11B2MAPTMEN1KMT2A
SCHEMBL6028966 0.77 SMN1; SMN2 (0.64) CYP11B1CYP11B2MAPTMEN1KMT2A
SCHEMBL5068556 0.77 MAPT (0.45) CYP11B1CYP11B2MAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2162454-B1 IMIDAZOPYRIDINE KINASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2013-01-02 EP disclosed
US-8093239-B2 Imidazopyridine kinase inhibitors GLAXOSMITHKLINE LLC (US) 2012-01-10 US disclosed
US-8093239-B2 Imidazopyridine kinase inhibitors GLAXOSMITHKLINE LLC (US) 2012-01-10 US disclosed
US-8093239-B2 Imidazopyridine kinase inhibitors GLAXOSMITHKLINE LLC (US) 2012-01-10 US disclosed
US-20100216779-A1 Imidazopyridine Kinase Inhibitors GLAXOSMITHKLINE LLC 2010-08-26 US disclosed
US-20100216779-A1 Imidazopyridine Kinase Inhibitors GLAXOSMITHKLINE LLC 2010-08-26 US disclosed
EP-2162454-A1 IMIDAZOPYRIDINE KINASE INHIBITORS GlaxoSmithKline LLC (US) 2010-03-17 EP disclosed
WO-2008150799-A1 IMIDAZOPYRIDINE KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2008-12-11 WO disclosed
US-20080300242-A1 Imidazopyridine Kinase Inhibitors GLAXOSMITHKLINE LLC 2008-12-04 US disclosed
US-20080300242-A1 Imidazopyridine Kinase Inhibitors GLAXOSMITHKLINE LLC 2008-12-04 US disclosed
US-20080300242-A1 Imidazopyridine Kinase Inhibitors GLAXOSMITHKLINE LLC 2008-12-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080300242-A1 Imidazopyridine Kinase Inhibitors ABL1, MAP3K19, MAP3K5 CYP11B1 2695/4885CYP11B2 2654/4885MAPT 2367/4885
US-20100216779-A1 Imidazopyridine Kinase Inhibitors ABL1, MAP3K19, MAP3K5 CYP11B1 2695/4885CYP11B2 2654/4885MAPT 2367/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.